Post the approval of first cell-based therapy, Carticel®, in 1997 in the US, the field has rapidly advanced and a number of such therapies are currently under development. The ‘Cell Therapy Manufacturing Market, 2017-2027’ report provides an extensive study of the rapidly growing market of cell therapy manufacturing and focuses both on contract manufacturers and cell therapy developers with in-house manufacturing facilities. Some of the most interesting insights from our study are presented below.
A Healthy Mix of Industry and Academic Organizations …
We came across over 110 organizations that are actively involved in the manufacturing of GMP certified cells for therapeutic purposes
… Dominated by the Presence of Several Contract Manufacturers
The landscape is well distributed among various stakeholders; led by contract manufacturers, some developers have established in-house capabilities
Clinical Scale Manufacturing, the Current Focus, is Driving the R&D Efforts
Majority of the players are actively involved in the clinical scale manufacturing of immunotherapies and adult stem cell therapies
US and EU: The Key Manufacturing Hubs
The US and EU, with maximum number of manufacturing facilities, have emerged as the primary manufacturing hubs
The Growing Interest is Also Evident from Several Partnerships Inked in the Recent Past
Several small and mid-sized cell therapy developers have collaborated with various contract manufacturers to outsource their early stage cell therapy candidates
With Cell Therapies Promising Significant Potential, CMOs Stand to Benefit Immensely
Our overall outlook is highly promising; the demand for manufacturing will significantly increase as these therapies advance through progressive stages of clinical validation
To know more please click here. For any queries / suggestions or if you’d like to get access to the full research results, please do not hesitate to contact us at firstname.lastname@example.org.